Susquehanna International Group LLP Grows Stock Position in Avalon Globocare Corp (OTCMKTS:AVCO)

Susquehanna International Group LLP raised its stake in shares of Avalon Globocare Corp (OTCMKTS:AVCO) by 42.4% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 101,081 shares of the company’s stock after buying an additional 30,092 shares during the period. Susquehanna International Group LLP owned about 0.13% of Avalon Globocare worth $263,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in shares of Avalon Globocare in the 2nd quarter valued at about $2,535,000. Vanguard Group Inc. increased its stake in shares of Avalon Globocare by 27.2% in the 2nd quarter. Vanguard Group Inc. now owns 714,159 shares of the company’s stock valued at $1,857,000 after purchasing an additional 152,648 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new position in shares of Avalon Globocare in the 2nd quarter valued at about $117,000. Bank of New York Mellon Corp purchased a new position in shares of Avalon Globocare in the 2nd quarter valued at about $88,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Avalon Globocare in the 2nd quarter valued at about $68,000.

AVCO stock traded up $0.13 during trading on Friday, hitting $1.86. The stock had a trading volume of 5,252 shares, compared to its average volume of 343,123. Avalon Globocare Corp has a twelve month low of $1.66 and a twelve month high of $13.50. The company’s 50-day moving average price is $2.05 and its two-hundred day moving average price is $2.74.

Avalon Globocare (OTCMKTS:AVCO) last posted its quarterly earnings data on Thursday, August 15th. The company reported ($0.06) earnings per share (EPS) for the quarter. Avalon Globocare had a negative return on equity of 81.16% and a negative net margin of 365.09%. The firm had revenue of $0.40 million during the quarter.

About Avalon Globocare

Avalon GloboCare Corp., together with its subsidiaries, engages in integrating and managing healthcare services and resources in the United States. It provides medical related consulting services and develops Avalon Cell and Avalon Rehab platforms that cover the areas of regenerative medicine, cell-based immunotherapy, and exosome technology.

Read More: What is a good rate of return for a mutual fund?

Institutional Ownership by Quarter for Avalon Globocare (OTCMKTS:AVCO)

Receive News & Ratings for Avalon Globocare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalon Globocare and related companies with MarketBeat.com's FREE daily email newsletter.